Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 ...
The contract replaces BARDA’s agreement with Venatorx, the company that licensed the oral antibiotic to Basilea.
Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LR Allschwi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback